BIIB
BIOGEN INC.
Biological Products, (No Diagnostic Substances)- 売上
- $9.9bn
- 時価総額
- $30.4bn
株価 $207.93 · 100株 2万円
| 期 | 23/12 | 24/12 | 25/12 |
|---|---|---|---|
| 売上 | $9.8bn | $9.7bn | $9.9bn |
| 成長率 | — | ▲1.6% | 2.2% |
| 総利益 | $11.6bn | $11.6bn | $11.6bn |
| 総利益率 | 118.3% | 120.3% | 117.7% |
| 販管費 | $2.5bn | $2.4bn | $2.4bn |
| 販管費率 | 25.9% | 24.8% | 24.6% |
| 営利 | $2.8bn | $2.8bn | $2.8bn |
| 営利率 | 28.9% | 29.4% | 28.7% |
| 純利益 | $1.2bn | $1.6bn | $1.3bn |
| PBR | 2.1 | 1.8 | 1.7 |
| PSR | 3.1 | 3.1 | 3.1 |
| PGPR | 2.6 | 2.6 | 2.6 |
| PER | 26 | 19 | 24 |
| ﾈｯﾄｷｬｯｼｭ | $2.9bn | $2.9bn | $2.9bn |
| EV/EBITDA | 8.3 | 7.8 | 7.6 |
| Rule of 40 | — | 28% | 31% |
| セールス効率 | — | — | 0% |
※Rule of 40は売上成長率＋営業利益率、セールス効率は売上総利益増加÷販管費増加（販管費増のときのみ）